Dow Chemical and Ampac Join Forces for PacXpert Packaging Technology

Zacks Equity Research

The Dow Chemical Company (DOW) announced that it has won the flexible packaging converter, Ampac, as the first licensee of its PacXpert packaging technology in North America. Ampac will be authorized to produce packages enabled by PacXpert Technology and will market the packages among its customer base under the Ampac CubePak name.

PacXpert packaging technology is a global trade name for Dow Chemical’s innovative packaging solution licensed by Smart Bottle Inc. It is an innovative technology that enables transition from larger conventional containers to flexible packaging options. The distinctive flexible stand-up pouch is durable, lightweight and cost effective. Moreover, the cube shaped package is shelf stable and can stand equally well upright or on its side. The transparent packaging enables consumers to see the contents and hence allow them to print on all four sides.

The PacXpert Technology has the potential for use in various household, institutional, food service and industrial applications including liquids and dry good products. It also provides a number of environmental benefits that help to reduce content waste by allowing consumers to achieve better product yield, and requires less raw materials during the manufacturing process when compared with rigid packaging alternatives.

PacXpert Technology also removes Just In Time (:JIT) delivery of rigid containers, augmenting shipping and warehouse organization and thus reducing carbon dioxide emissions. When filled, the pouches form into a cube improving pack density.

With this technology both Dow Chemical and Ampac can offer sustainability benefits and convenience to its customers.

Dow Chemical is a Zacks Rank #3 (Buy) stock.

Some better ranked stocks in the chemical space include Compass Minerals International Inc. (CMP), Eastman Chemical Company (EMN) and Koninklijke DSM N.V. (RDSMY). While Compass Minerals sports a Zacks Rank #1 (Strong Buy), Eastman Chemical and Koninklijke DSM have a Zacks Rank #2 (Buy).
 

Read the Full Research Report on DOW
Read the Full Research Report on EMN
Read the Full Research Report on CMP
Read the Full Research Report on RDSMY


Zacks Investment Research